TWiV 895: COVID-19 clinical update #112 with Dr. Daniel Griffin
b'
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.
Subscribe (free):\\xa0Apple Podcasts,\\xa0Google Podcasts,\\xa0RSS,\\xa0email
Become a\\xa0patron\\xa0of\\xa0TWiV!
Links for this episode
- Seroprevalence of\\xa0Infection-Induced Antibodies\\xa0(CDC)\\xa0
- Authorization for Vaccine\\xa0in Young Children Filed (Moderna)
- Public Health Impact\\xa0of Vaccines in US (BMJ)
- FDA authorizes first\\xa0approved treatment for children\\xa0(FDA)
- Phase 2 Data\\xa0for Sabizabulin (Veru Pharma)\\xa0
- Clinical Characteristics of\\xa0Post Infection Inflammation\\xa0(The Lancet)
- Fact Sheet for Providers on\\xa0Evusheld\\xa0(FDA)
- Fact Sheet for Providers on\\xa0Paxlovid\\xa0(FDA)
- Provider Referral\\xa0for EvuSheld (Northwell Health)
- Contribute to\\xa0ASTMH fundraiser at PWB
- Dr. Griffin\\u2019s treatment guide (pdf)
- Letters read\\xa0on TWiV 895
- Timestamps by Jolene. Thanks!
Intro music is by\\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv